Microbial Genomics Market: Market Size & Forecast 2026

The microbial genomics market is a rapidly expanding segment of the broader genomics industry, encompassing microbial genomics platforms, microbiome sequencing services, metagenomics, microbial gene editing services, and human microbiome applications. In 2025, the microbial genomics market alone is estimated at approximately $2.46 billion, while the broader ecosystem, including microbiome sequencing services ($3.05 billion), metagenomics ($3.3 billion), the human microbiome market ($1.6 billion), and microbial gene editing services ($9.0 billion), collectively reflects the overall market landscape. The wider genomics market is projected to grow from $47.07 billion in 2025 to $85.09 billion by 2030 at a 12.6% CAGR, and to $186.64 billion by 2035 at a 15.0% CAGR, with microbial genomics representing one of the fastest-growing sub-segments driven by clinical, pharmaceutical, and research applications.

• •The microbial genomics market is a multi-layered segment spanning sequencing, gene editing, and microbiome analysis technologies
• •Combined sub-segments (microbial genomics, microbiome sequencing, metagenomics, human microbiome, and gene editing) represent a substantial portion of the broader genomics industry
• •The overall genomics market is expected to reach between $85 billion and $187 billion by 2030-2035

The primary driver of market expansion is the rising global prevalence of infectious diseases, which has heightened demand for microbial genomic surveillance, diagnostics, and research. Advances in next-generation sequencing (NGS) platforms, widely adopted across research and clinical settings, have made microbial genome sequencing faster, cheaper, and more accessible. CRISPR/Cas9 and other gene editing tools have unlocked significant opportunities in microbial strain engineering for pharmaceutical and biotechnology applications, with the microbial gene editing services market alone forecast to grow at a 19.0% CAGR from $9.0 billion in 2025 to $51.3 billion by 2035. Additionally, government genomic research funding and the push toward precision medicine are accelerating investments in microbiome and metagenomics research.

• •Rising infectious disease burden is driving demand for microbial genomic diagnostics and surveillance tools
• •Next-generation sequencing (NGS) adoption and declining sequencing costs are expanding market accessibility
• •CRISPR/Cas9-based microbial gene editing is projected to reach $51.3 billion by 2035 at a 19.0% CAGR

The microbial genomics market is broadly segmented into products (instruments, reagents, software), services (sequencing, bioinformatics, data analysis), and applications (clinical diagnostics, pharmaceutical research, food safety, environmental monitoring). The metagenomics segment, valued at $3.3 billion in 2025, is forecast to reach $11.37 billion by 2034 at a 14.74% CAGR, supported by broader access to compact and affordable sequencing instruments. The microbiome sequencing services market, at $3.05 billion in 2025, is projected to reach $12.13 billion by 2034 at a 16.09% CAGR, fueled by expanding clinical trial programs and outsourced pharmaceutical research. The human microbiome market, growing from $1.6 billion to $8.9 billion by 2034 at a 20.9% CAGR, reflects surging demand for precision medicine and lifestyle-related chronic disease therapeutics.

• •Metagenomics ($3.3 billion in 2025, 14.74% CAGR) is expanding due to affordable sequencing instruments
• •Microbiome sequencing services ($3.05 billion, 16.09% CAGR) are driven by clinical trial outsourcing and pharma R&D
• •The human microbiome market ($1.6 billion, 20.9% CAGR) is the fastest-growing sub-segment, fueled by precision medicine demand

What are the recent trends and outlook?

Looking ahead, the microbial genomics market is expected to maintain a robust growth trajectory through the early 2030s, driven by converging technological, clinical, and commercial forces. Long-read sequencing technologies, particularly those offered by Oxford Nanopore and Pacific Biosciences, are gaining momentum for their ability to resolve complex microbial genomes. Integration of artificial intelligence and machine learning into microbial genomic data analysis is accelerating pathogen identification, antimicrobial resistance profiling, and microbiome-based drug discovery. The oncology and drug discovery sectors represent particularly high-growth application areas, with the human microbiome sequencing market projected at a 20.8% CAGR through 2031. Government genomic research funding programs, continued NGS platform adoption, and the broadening clinical utility of microbial genomics in infectious disease management collectively position the market for sustained long-term expansion.

• •Long-read sequencing technologies are enabling more complete and accurate microbial genome assemblies
• •AI and machine learning integration is enhancing pathogen identification, AMR profiling, and microbiome drug discovery
• •Oncology research and drug discovery applications, alongside government genomic funding, are key tailwinds through 2031